Cancer drug fund extension relieves firms
This article was originally published in Scrip
England's Cancer Drugs Fund is set to live on for another two years beyond the date it was supposed to be superseded by a new pricing set up. Manufacturers of oncology drugs will likely welcome another two years of greater stability while uncertainty over the UK's pricing landscape continues.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.